CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 58 enrolled
Drug / intervention
5-Fluoro-2-Deoxycytidine (FdCyd) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00359606
NCT00359606Phase 1Completed
CompareCT.gov

Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine

City of Hope Medical Center·interventional·Posted Aug 2, 2006·Updated May 6, 2015

In Brief

A Phase 1 clinical trial evaluating 5-Fluoro-2-Deoxycytidine (FdCyd), Laboratory Biomarker Analysis, and 2 other interventions for Neoplasms. Completed, enrolled 58 participants across 4 sites.

Detailed Summary

This phase I trial studies the side effects and best dose of 5-fluoro-2-deoxycytidine when given together with tetrahydrouridine in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Drugs used in chemotherapy, such as 5-fluoro-2-deoxycytidine and tetrahydrouridine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2, 2006
Enrollment StartApr 1, 1999
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 13.2 yearsPosted 19.9 years ago

Interventions

5-Fluoro-2-Deoxycytidine (FdCyd)drug

Given PO and IV

Laboratory Biomarker Analysisother

Correlative Studies

Pharmacological Studyother

Correlative Studies

Tetrahydrouridine (THU)drug

Given PO and IV